MX2023004146A - O-acetilserina para uso de la misma en la prevención y tratamiento de intolerancia a la glucosa y las enfermedades asociadas. - Google Patents
O-acetilserina para uso de la misma en la prevención y tratamiento de intolerancia a la glucosa y las enfermedades asociadas.Info
- Publication number
- MX2023004146A MX2023004146A MX2023004146A MX2023004146A MX2023004146A MX 2023004146 A MX2023004146 A MX 2023004146A MX 2023004146 A MX2023004146 A MX 2023004146A MX 2023004146 A MX2023004146 A MX 2023004146A MX 2023004146 A MX2023004146 A MX 2023004146A
- Authority
- MX
- Mexico
- Prior art keywords
- glucose intolerance
- acetylserine
- prevention
- treatment
- associated diseases
- Prior art date
Links
- 208000002705 Glucose Intolerance Diseases 0.000 title abstract 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 title abstract 5
- VZXPDPZARILFQX-BYPYZUCNSA-N O-acetyl-L-serine Chemical compound CC(=O)OC[C@H]([NH3+])C([O-])=O VZXPDPZARILFQX-BYPYZUCNSA-N 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La O-acetilserina para uso de la misma en la prevención y tratamiento de intolerancia a la glucosa y las enfermedades asociadas. La presente solicitud de patente se refiere a O-acetilserina, o una sal o derivado de la misma, para usarse en el tratamiento y/o prevención de intolerancia a la glucosa y/o una o más enfermedades asociadas con intolerancia a la glucosa en un individuo. También se refiere a una composición para usarse en el tratamiento y/o prevención de intolerancia a la glucosa y/o una o más enfermedades asociadas con intolerancia a la glucosa en un individuo, que comprende una O-acetilserina, o una sal o derivado de la misma, y un vehículo fisiológicamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2010231A FR3114740B1 (fr) | 2020-10-07 | 2020-10-07 | O-acétylsérine pour son utilisation dans la prévention et le traitement de l’intolérance au glucose et les maladies associées |
| PCT/EP2021/077779 WO2022074154A1 (fr) | 2020-10-07 | 2021-10-07 | O-acétylsérine pour son utilisation dans la prévention et le traitement de l'intolérance au glucose et les maladies associées |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004146A true MX2023004146A (es) | 2023-06-19 |
Family
ID=74045718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004146A MX2023004146A (es) | 2020-10-07 | 2021-10-07 | O-acetilserina para uso de la misma en la prevención y tratamiento de intolerancia a la glucosa y las enfermedades asociadas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240024274A1 (es) |
| EP (1) | EP4225294A1 (es) |
| JP (1) | JP2023545272A (es) |
| KR (1) | KR20230107229A (es) |
| CN (1) | CN117098534A (es) |
| AU (1) | AU2021356135A1 (es) |
| CA (1) | CA3194891A1 (es) |
| FR (1) | FR3114740B1 (es) |
| IL (1) | IL301962A (es) |
| MX (1) | MX2023004146A (es) |
| WO (1) | WO2022074154A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10107002A1 (de) * | 2001-02-15 | 2002-08-29 | Consortium Elektrochem Ind | Verfahren zur fermentativen Herstellung von O-Acetyl-L-Serin |
-
2020
- 2020-10-07 FR FR2010231A patent/FR3114740B1/fr active Active
-
2021
- 2021-10-07 EP EP21783026.4A patent/EP4225294A1/fr active Pending
- 2021-10-07 IL IL301962A patent/IL301962A/en unknown
- 2021-10-07 CN CN202180077798.8A patent/CN117098534A/zh active Pending
- 2021-10-07 WO PCT/EP2021/077779 patent/WO2022074154A1/fr active Application Filing
- 2021-10-07 CA CA3194891A patent/CA3194891A1/fr active Pending
- 2021-10-07 US US18/247,928 patent/US20240024274A1/en active Pending
- 2021-10-07 JP JP2023521308A patent/JP2023545272A/ja active Pending
- 2021-10-07 MX MX2023004146A patent/MX2023004146A/es unknown
- 2021-10-07 KR KR1020237015449A patent/KR20230107229A/ko unknown
- 2021-10-07 AU AU2021356135A patent/AU2021356135A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117098534A (zh) | 2023-11-21 |
| US20240024274A1 (en) | 2024-01-25 |
| FR3114740A1 (fr) | 2022-04-08 |
| WO2022074154A1 (fr) | 2022-04-14 |
| EP4225294A1 (fr) | 2023-08-16 |
| KR20230107229A (ko) | 2023-07-14 |
| FR3114740B1 (fr) | 2022-11-04 |
| AU2021356135A1 (en) | 2023-06-08 |
| IL301962A (en) | 2023-06-01 |
| JP2023545272A (ja) | 2023-10-27 |
| CA3194891A1 (fr) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009164A (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos. | |
| AU2008232453A8 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
| TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
| NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
| JOP20190281A1 (ar) | مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| MX2021002321A (es) | Nuevos metodos. | |
| NZ599265A (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2021002322A (es) | Nuevos metodos. | |
| MX2023006146A (es) | Composiciones bacterianas diseñadas para tratar la enfermedad de injerto contra huésped. | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| WO2016182139A3 (ko) | 자근 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물 | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2022005388A (es) | Compuestos de pirrolidina y piperidina. | |
| MX2022010093A (es) | Tafoxiparina para el tratamiento de la preeclampsia. | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| MX2023004146A (es) | O-acetilserina para uso de la misma en la prevención y tratamiento de intolerancia a la glucosa y las enfermedades asociadas. | |
| WO2020109233A3 (en) | Trmt2a inhibitors for use in the treatment of polyglutamine diseases | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| MX2022014577A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| NZ584766A (en) | Method, composition, and article of manufacture for providing alpha-1 antitrypsin |